ClinicalTrials.gg
CompletedNCT06873516Updated Jul 1, 2026

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

A Phase 2 interventional study of EVO756 and EVO756 in Chronic Spontaneous Urticaria, sponsored by Evommune, Inc.. Completed at 53 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Evommune, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
24th of 58
182 · median 132
Started
2025
with 8 others
Phase 2
23 of 64
4 open now
Registered
54th of 64
by date

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 24th largest by enrollment of the 58 interventional ones that give a count, is one of 9 that started in 2025, is one of 23 in phase 2, and was the 54th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

03

Conditions studied

  • Chronic Spontaneous Urticaria

Keywords

  • chronic spontaneous urticaria
  • CSU
  • chronic hives
  • hives
  • idiopathic urticaria
  • urticaria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
  • Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
  • Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.

Exclusion criteria

Exclusion Criteria:

  • Any abnormality in laboratory evaluations, physical examinations, vital signs, or at Screening, according to the Investigator's discretion.
  • Use of certain medications.
  • History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
  • Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Dose 1

    Orally administered EVO756, dose 1

    Drug: EVO756

  • Experimental
    Dose 2

    Orally administered EVO756, dose 2

    Drug: EVO756

  • Experimental
    Dose 3

    Orally administered EVO756, dose 3

    Drug: EVO756

  • Placebo comparator
    Placebo control

    Orally administered placebo control

    Drug: Placebo control

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in UAS7

    Time frame: Week 12

Secondary outcomes

  1. Percent change from baseline in UAS7

    Time frame: Week 12

  2. Mean and percent change from baseline in UAS7

    Time frame: Weeks 1, 2, 4, 8

  3. Mean and percent change from baseline in ISS7

    Time frame: Weeks 1, 2, 4, 8, 12

  4. Mean and percent change from baseline in HSS7

    Time frame: Weeks 1, 2, 4, 8, 12

  5. Mean and percent change from baseline in AAS7

    Time frame: Weeks 1, 2, 4, 8, 12

  6. Proportion of subjects achieving UAS7 ≤ 6

    Time frame: Weeks 1, 2, 4, 8, 12

  7. Proportion of subjects achieving UAS7 = 0

    Time frame: Weeks 1, 2, 4, 8, 12

07

Study locations

53 sites
  • Cahaba Dermatology Skin Health Center
    Birmingham, Alabama 35244, United States
  • Velocity Clinical Research, Mobile
    Mobile, Alabama 36608, United States
  • Center for Dermatology Clinical Research
    Fremont, California 94538, United States
  • Antelope Valley Clinical Trials
    Lancaster, California 93534, United States
  • Northridge Clinical Trials
    Northridge, California 91325, United States
  • NorthBay Clinical Research
    Santa Rosa, California 95405, United States
  • Integrated Research of Inland
    Upland, California 91786, United States
  • FOMAT Medical Research
    Ventura, California 93003, United States
  • AMR Fort Myers
    Fort Myers, Florida 33912, United States
  • Advanced Clinical Research Institute
    Tampa, Florida 33607, United States
  • Sneeze, Wheeze & Itch Associates LLC
    Normal, Illinois 61761, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • The Iowa Clinic
    West Des Moines, Iowa 50266, United States
  • Hutchinson Clinic
    Hutchinson, Kansas 67502, United States
  • Bluegrass Allergy Care
    Lexington, Kentucky 40509, United States
  • Delricht Research Louisville
    Louisville, Kentucky 40205, United States
  • Delricht Research Louisiana
    Baton Rouge, Louisiana 70809, United States
  • Velocity Clinical Research, Lafayette
    Lafayette, Louisiana 70508, United States
  • Delricht Research
    New Orleans, Louisiana 70115, United States
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224, United States
  • Boston Specialists
    Boston, Massachusetts 02111, United States
  • MI Skin Innovations
    Northville, Michigan 48167, United States
  • DelRicht Research - Town Center Dermatology
    Wildwood, Missouri 63040, United States
  • Vitality Clinical Trials
    Woodbury, New York 11797, United States
  • Allergy Partners Clinical Research
    Asheville, North Carolina 28803, United States
  • Delricht Research - Priority Care
    Charlotte, North Carolina 28205, United States
  • Piedmont Healthcare
    Statesville, North Carolina 28625, United States
  • Optima Research Boardman
    Boardman, Ohio 44512, United States
  • DOCS Dermatology Research
    Canal Winchester, Ohio 43110, United States
  • Bernstein Clinical Research Center
    Cincinnati, Ohio 45236, United States
  • Toledo Institute of Clinical Research
    Toledo, Ohio 43617, United States
  • AMR Myrtle Beach
    Myrtle Beach, South Carolina 29572, United States
  • National Allergy and Asthma Research
    North Charleston, South Carolina 29420, United States
  • Delricht Research Smyrna
    Smyrna, Tennessee 37167, United States
  • Austin Regional Clinic ARC Clinical Research
    Austin, Texas 78726, United States
  • Studies in Dermatology
    Cypress, Texas 77429, United States
  • Western Sky Medical Research
    El Paso, Texas 79912, United States
  • Delricht Research - Lockhard Matter Dermatology
    Prosper, Texas 75078, United States
  • AMR Utah
    Layton, Utah 84041, United States
  • Seattle Clinical Research Center
    Seattle, Washington 98104, United States
  • Allergy, Asthma, and Sinus Center
    Greenfield, Wisconsin 53228, United States
  • Dandelion Allergy Centre
    Mississauga, Ontario L4W 5K3, Canada
  • Allergy Research Canada
    Niagara Falls, Ontario L2H 1H5, Canada
  • Red Maple Trials
    Ottawa, Ontario K1H 1E4, Canada
  • Centre de Recherche Saint-Louis - Montréal
    Montreal, Quebec H1Y 3L1, Canada
  • Centre de Recherche Saint-Louis
    Québec, Quebec G1W 4R4, Canada
  • Dermatology and Ophthalmology Kume Clinic
    Sakai, Osaka 5938324, Japan
  • Yoshikawa Skin Clinic
    Takatsuki, Osaka 5690824, Japan
  • Osaka Medical and Pharmaceutical University Hospital
    Takatsuki, Osaka 5698686, Japan
  • Mita Dermatology
    Minato-Ku, Tokyo 1080014, Japan
  • ThinkPark Dermatology Clinic
    Shinagawa-Ku, Tokyo 1416003, Japan
  • Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
    Tachikawa, Tokyo 1900023, Japan
  • Ikebukuro Nishiguchi Fukurou Dermatology
    Toshima-ku, Tokyo 1710021, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2026, 14 months.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2025
First posted
Mar 12, 2025
StartActual
Mar 20, 2025
Primary completionActual
May 29, 2026
CompletionActual
Jun 5, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06873516
Lead sponsor
Evommune, Inc.
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Mar 20, 2025
Primary completion
May 29, 2026
Completion
Jun 5, 2026
Last update
Jul 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EVO756

Start the discussion